Sanofi Pasteur Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$403.0M
Doctors Paid
63,115
Transactions
177,035
2024 Total
$42.1M
Payment Breakdown by Category
Research$391.5M (97.1%)
Consulting$3.6M (0.9%)
Food & Beverage$2.9M (0.7%)
Travel$955,453 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $391.5M | 26,565 | 97.1% |
| Consulting Fee | $3.6M | 1,616 | 0.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.2M | 3,642 | 0.8% |
| Food and Beverage | $2.9M | 141,545 | 0.7% |
| Travel and Lodging | $955,453 | 2,590 | 0.2% |
| Grant | $381,346 | 19 | 0.1% |
| Gift | $344,389 | 568 | 0.1% |
| Charitable Contribution | $114,206 | 4 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $96,225 | 79 | 0.0% |
| Education | $32,900 | 407 | 0.0% |
Payments by Type
Research
$391.5M
26,565 transactions
General
$11.5M
150,470 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| STA00011 Stamaril Yellow Fever | $45.2M | 1 | 1,122 |
| STA00011 Stamaril Yellow Fever | $25.4M | 1 | 638 |
| Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines With AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Two Monovalent and One Bivalent) | $22.4M | 19 | 1,179 |
| Examining Vaccine Effectiveness of Flublok relative to SD inactivated Influenza Vaccine among Kaiser Permanente Northern California Members aged 18-64 years | $22.1M | 0 | 11 |
| Effectiveness of Flublok relative to Standard Dose QIV among Kaiser Permanente Norther California members | $19.4M | 0 | 1 |
| A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | $14.0M | 0 | 737 |
| MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers | $12.7M | 0 | 1,987 |
| MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers | $11.6M | 0 | 2,080 |
| Comparative Effectiveness of Recombinant Influenza Vaccine versus Standard Dose Quadrivalent Influenza Vaccine in U.S. Nursing Home | $11.5M | 0 | 1,176 |
| Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | $11.4M | 0 | 373 |
| H 030 014 Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection | $10.3M | 0 | 1,807 |
| Comparative Effectiveness of Recombinant Influenza Vaccine versus Standard Dose Quadrivalent Influenza Vaccine in U.S. Nursing Homes | $9.9M | 0 | 5 |
| Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | $9.0M | 0 | 379 |
| A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older | $8.8M | 0 | 315 |
| Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older | $8.7M | 0 | 395 |
| A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | $7.8M | 33 | 638 |
| A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | $6.7M | 1 | 455 |
| QHD00013 Ph III Higher Volume Quadrivalent HD in Elderly US | $6.1M | 0 | 183 |
| A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older | $6.0M | 11 | 885 |
| A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | $5.4M | 0 | 214 |
| Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years. | $4.9M | 0 | 163 |
| Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults | $4.3M | 0 | 270 |
| A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | $4.2M | 0 | 195 |
| Comparative Effectiveness of Recombinant Influenza Vaccine versus Standard Dose Quadrvalent Influenza Vaccine in U.S. Nursing Homes | $4.0M | 0 | 5 |
| VAT00001 Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (with or without adjuvant) in Healthy Adults 18 Years of Age and Older | $3.9M | 0 | 101 |
| A Phase I, Dose-escalation, Parallel-group, Randomized, Multi-center Study to Assess Safety and Immunogenicity of an RSV/hMPV mRNA Vaccine Candidate in Healthy Participants Aged 18 to 49 Years and 60 Years and Older. | $3.7M | 0 | 160 |
| Safety and Immunogenicity of a First In-Human Influenza mRNA Vaccine in Healthy Adults Aged 18 to 49 Years | $3.4M | 0 | 178 |
| A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. | $3.2M | 0 | 42 |
| INVESTED Study | $3.2M | 0 | 12 |
| MET43 Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults Aged 10 to 55 Years | $3.0M | 0 | 354 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. Stanley Plotkin, Md, MD | Clinical & Laboratory Immunology | Doylestown, PA | $239,448 | $0 |
| Christopher Belcher, Md, MD | Pediatric Infectious Diseases | Carmel, IN | $224,002 | $0 |
| Joseph Domachowske, Md, MD | Pediatric Infectious Diseases | Syracuse, NY | $202,273 | $0 |
| Dr. Jaime Fergie, M.d, M.D | Pediatric Infectious Diseases | Corpus Christi, TX | $200,927 | $0 |
| Dr. Michael Decker, Md, MD | Infectious Disease | Baxter, TN | $197,457 | $0 |
| Stefan Gravenstein, Md, MD | Geriatric Medicine | Providence, RI | $191,858 | $0 |
| Dr. Tina Tan, Md, MD | Pediatric Infectious Diseases | Chicago, IL | $174,294 | $0 |
| Dr. Evan Anderson, M.d, M.D | Pediatric Infectious Diseases | Atlanta, GA | $136,142 | $0 |
| Martin Mahoney, Md, MD | Family Medicine | Buffalo, NY | $125,957 | $0 |
| Dr. Mohammad Madjid, Md, MD | Internal Medicine | Ventura, CA | $123,284 | $0 |
| Dr. Marvin Bittner, M.d, M.D | Infectious Disease | Omaha, NE | $122,918 | $0 |
| Archana Chatterjee, M.d, M.D | Pediatrics | Sioux Falls, SD | $116,664 | $0 |
| Eric Simoes, Md, MD | Pediatric Infectious Diseases | Aurora, CO | $110,592 | $0 |
| Dr. Gary Marshall, Md, MD | Pediatrics | Louisville, KY | $110,494 | $0 |
| Dr. Kamaljit Singh, M.d, M.D | Medical Microbiology | Chicago, IL | $109,427 | $0 |
| Dr. Wayne Dankner, Md, MD | Specialist | Durham, NC | $108,990 | $0 |
| Dr. Peter Sebeny, M.d, M.D | Infectious Disease | Newburyport, MA | $96,785 | $0 |
| Robert Belshe, Md, MD | Infectious Disease | Saint Louis, MO | $93,854 | $0 |
| Maria Mejias, Md, MD | Pediatrics | Memphis, TN | $90,342 | $0 |
| Dr. Daniel Fraschetti, D.o, D.O | Pediatrics | Yucca Valley, CA | $81,331 | $0 |
| Todd Wolynn, Md, MD | Pediatrics | Pittsburgh, PA | $78,875 | $0 |
| Flor De Maria Munoz, Md, MD | Pediatric Infectious Diseases | Houston, TX | $76,909 | $0 |
| Octavio Ramilo, Md, MD | Pediatric Infectious Diseases | Memphis, TN | $74,365 | $0 |
| Philip Krause, M.d, M.D | Infectious Disease | Potomac, MD | $74,147 | $0 |
| Stephen Scholand, Md, MD | Internal Medicine | Meriden, CT | $73,567 | $0 |
Ad
Top Products
- YELLOW FEVER $42.2M
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE $33.3M
Associated Products (22)
- YELLOW FEVER $42.2M
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE $33.3M
- FLUBLOK QUADRIVALENT $25.3M
- MENACYW CONJUGATE VACCINE $19.9M
- FLUZONE QUADRIVALENT $19.5M
- CLOSTRIDIUM DIFFICILE TOXOID VACCINE $10.5M
- FLUZONE $8.5M
- PURIFIED VERO RABIES VACCINE $3.5M
- FLUZONE HIGH-DOSE $3.1M
- FLUZONE QUADRIVALENT NORTHERN HEMISPHERE $2.6M
- MENB VACCINE $1.8M
- TETRAVALENT DENGUE VACCINE $917,382
- ADACEL $844,513
- MENACTRA $841,484
- BEYFORTUS $801,227
- C DIFFICILE $632,005
- MENQUADFI $433,193
- PENTACEL $407,745
- PNEUMOCOCCAL CONJUGATE VACCINE $389,823
- DENGVAXIA $129,871
- HSV VACCINE $121,407
- QUADRACEL $72,462
Payment Categories
- Food & Beverage $2.9M
- Consulting $3.6M
- Travel & Lodging $955,453
- Research $391.5M
About Sanofi Pasteur Inc.
Sanofi Pasteur Inc. has made $403.0M in payments to 63,115 healthcare providers, recorded across 177,035 transactions in the CMS Open Payments database. In 2024, the company paid $42.1M. The top product by payment volume is YELLOW FEVER ($42.2M).
Payments were distributed across 258 medical specialties. The top specialty by payment amount is Pediatrics ($3.1M to 19,550 doctors).
Payment categories include: Food & Beverage ($2.9M), Consulting ($3.6M), Research ($391.5M), Travel & Lodging ($955,453).
Sanofi Pasteur Inc. is associated with 22 products in the CMS Open Payments database, including YELLOW FEVER, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, and FLUBLOK QUADRIVALENT.